AI assistant
Oxurion NV — Major Shareholding Notification 2015
May 19, 2015
3987_mrq_2015-05-19_1eade480-c6e9-4696-bd46-da64925a8acb.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Regulated Information ‐ Transparency Statement
Philippe Baron Vlerick confirms 3.6% shareholding in ThromboGenics nv
Leuven, Belgium, 19 May 2015 – Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR)received a transparency notification on 18 May 2015 from Philippe Baron Vlerick and controlled entities.
Mr. Vlerick notified that on 14 May 2015, a total of 1,299,732 shares representing 3.6% of the current 36.094.349 outstanding ThromboGenics shares were held by himself and through controlled entities.
On May 19, 2015, based on all received transparency declarations received, ThromboGenics NV is aware of the following participations:
| Shareholder | number of securities | % of voting rights |
|---|---|---|
| Mr Landon T. Clay and all |
||
| entities controlled by him | 1,071,061 | 2.97% |
| Mr Thomas M. Clay and all |
||
| entities controlled by him | 2,790,062 | 7.73% |
| Biggar Ltd | 2,111,121 | 5.9% |
| Norges Bank | 1,065,605 | 2.95% |
| Philippe Vlerick and all entities controlled by him |
1,299,732 | 3.6% |
END
For further information please contact:
| ThromboGenics | Citigate Dewe Rogerson |
|---|---|
| Wouter Piepers, Global Head of Corporate Communications & IR +32 16 75 13 10 / +32 478 33 56 32 [email protected] |
David Dible/Malcolm Robertson Tel: +44 20 7282 2867 [email protected] |
About ThromboGenics
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States.
ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.
Important information about forward‐looking statements
Certain statements in this press release may be considered "forward‐looking". Such forward‐looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward‐looking statements will materialize and does not assume an obligation to update or revise any forward‐looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward‐ looking statement is contained in the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.